Avacta has announced a joint venture with Daewoong Pharmaceuticals to develop mesenchymal stem cell (MSC) therapies incorporating Affimers. The joint venture (JV), will be based in South Korea and entirely funded by Daewoong with Avacta providing no financial investment. Avacta will develop Affimers (and be reimbursed by Daewoong for all research and development costs) for several undisclosed targets in inflammatory and autoimmune disorders. Avacta will have a 45% shareholding in the new comp
08 Jan 2020
Avacta Group - New JV gives further validation to Affimers
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Avacta Group - New JV gives further validation to Affimers
Avacta Group PLC (AVCT:LON) | 45.0 -0.1 (-0.7%) | Mkt Cap: 161.6m
- Published:
08 Jan 2020 -
Author:
Dr Daniel Wilkinson -
Pages:
2
Avacta has announced a joint venture with Daewoong Pharmaceuticals to develop mesenchymal stem cell (MSC) therapies incorporating Affimers. The joint venture (JV), will be based in South Korea and entirely funded by Daewoong with Avacta providing no financial investment. Avacta will develop Affimers (and be reimbursed by Daewoong for all research and development costs) for several undisclosed targets in inflammatory and autoimmune disorders. Avacta will have a 45% shareholding in the new comp